Sensei Biotherapeutics, Inc. (NASDAQ:FTH – Get Free Report) CEO Anand Kiran Parikh purchased 2,806 shares of Sensei Biotherapeutics stock in a transaction on Monday, June 22nd. The shares were acquired at an average cost of $19.76 per share, for a total transaction of $55,446.56. Following the purchase, the chief executive officer owned 764,234 shares in the company, valued at approximately $15,101,263.84. This trade represents a 0.37% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Sensei Biotherapeutics Stock Performance
FTH stock opened at $24.67 on Friday. Sensei Biotherapeutics, Inc. has a 52-week low of $6.32 and a 52-week high of $36.76.
Analyst Upgrades and Downgrades
A number of analysts have issued reports on the company. HC Wainwright initiated coverage on Sensei Biotherapeutics in a research note on Monday. They issued a “buy” rating and a $60.00 price target on the stock. BTIG Research raised shares of Sensei Biotherapeutics to a “strong-buy” rating in a research note on Thursday, June 11th. Finally, Weiss Ratings began coverage on shares of Sensei Biotherapeutics in a report on Wednesday, June 17th. They set a “sell (d-)” rating on the stock. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $60.00.
Sensei Biotherapeutics Company Profile
Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.
Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.
See Also
- Five stocks we like better than Sensei Biotherapeutics
- MDA Space Targets US Defense Market With $620M Acquisition
- Carnival’s Second Quarter: Is the Stock Still Complicated?
- Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
- Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal
Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
